Vanguard Group Inc Bolt Biotherapeutics, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,037,603 shares of BOLT stock, worth $767,826. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,037,603

Previous 931,129 11.43%

Holding current value

$767,826

Previous $1.04 Million 39.35%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.01 - $1.4 $107,538 - $149,063	106,474 Added 11.43%	1,037,603 $1.45 Million
Q4 2023 Feb 14, 2024	BUY	$0.85 - $1.12 $5,834 - $7,687	6,864 Added 0.74%	931,129 $1.04 Million
Q3 2023 Nov 14, 2023	SELL	$0.98 - $1.46 $3,930 - $5,856	-4,011 Reduced 0.43%	924,265 $961,000
Q4 2022 Feb 10, 2023	SELL	$1.26 - $1.48 $15,111 - $17,749	-11,993 Reduced 1.28%	928,276 $1.21 Million
Q3 2022 Nov 14, 2022	BUY	$1.72 - $2.61 $86,820 - $131,744	50,477 Added 5.67%	940,269 $1.39 Million

Q2 2022 Aug 12, 2022	BUY	$1.41 - $2.91 $59,194 - $122,167	41,982 Added 4.95%	889,792 $1.82 Million
Q1 2022 May 13, 2022	SELL	$2.74 - $4.82 $411,923 - $724,624	-150,337 Reduced 15.06%	847,810 $2.32 Million
Q4 2021 Feb 14, 2022	BUY	$4.19 - $13.97 $20,459 - $68,215	4,883 Added 0.49%	998,147 $4.89 Million
Q3 2021 Nov 12, 2021	BUY	$11.15 - $18.6 $3.86 Million - $6.44 Million	346,194 Added 53.5%	993,264 $12.6 Million
Q2 2021 Aug 13, 2021	BUY	$15.4 - $31.46 $9.96 Million - $20.4 Million	647,070 New	647,070 $10 Million

Others Institutions Holding BOLT

# of Institutions

Shares Held

24.3M

Call Options Held

Put Options Held

View Full List

About Bolt Biotherapeutics, Inc.

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $27.9M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

More about BOLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Bolt Biotherapeutics, Inc. Transaction History